Translate this page into:
Author's Reply
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Dear Reader,
We, the authors of “Unilateral Graves' disease: The lesser known,” thank you for your warm response and thought-provoking queries. Here, we are answering the questions to the best of our knowledge, after going through the given history and follow-up of the patients.
The mean duration of symptoms for these patients was 11.8 months (2–48 months). Three of the 15 patients were on antithyroid drugs before nuclear medicine consultation. One patient was on antithyroid drugs for 18 months and the other two patients were on for 1 year.
-
Japan Thyroid Association uses the criteria as:
Clinical: Enlarged gland, symptoms of hyperthyroidism, and ophthalmopathy
-
Laboratory criteria: Elevated free T3 and T4 levels, serum thyroid-stimulating hormone levels <0.1 mIU/L, elevated uptake on the scan, and presence of antithyroid antibodies.
Of these criteria, antithyroid antibodies were not tested in any of the patients and all other laboratory criteria were fulfilled.
Only few patients had overt eye signs of Graves' disease. None of the patients underwent thyroidectomy. Either the patients are on antithyroid drugs or the patients underwent definitive radioactive iodine ablation. Remission after hemithyroidectomy in these patients has to be studied, and we do not have any data of the same.